Efficacy of the Combination of " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate in Adult Patients With Schizophrenic or Related Disorder : A Multicenter Randomized Controlled Trial

Intramuscular injection (IMI) is the process of administering a drug treatment into muscle tissue. The transmission of skills in this care practice is essentially based on the experience of peers. In France, there are no official guidelines for this technical procedure.
Haloperidol decanoate is widely used in psychiatry. This long-acting antipsychotic treatment considerably reduces the risk of relapse and hospitalization. It is administered by IMI. This treatment is invasive, painful and risks complications for the patient. Nurses must ensure that the treatment is as painless as possible, and adapt their practice in line with current recommendations.
Among the various IMI techniques available, the "Z-track" and the "Airlock" limit leakage into subcutaneous tissues when the needle is withdrawn, by locking the active product into the muscular tissues. According to an exploratory study (n=303), 73% of nurses observe active product leakage after injections, and 89% of nurses are not familiar with either the "Z-track" or "Airlock" techniques.
Many foreign studies have been carried out to demonstrate the relevance of these techniques, particularly in terms of pain reduction during treatment, but the results have yet to be confirmed.
The investigators hypothesize that the combined use of the "Z-track" and "Airlock" techniques during intramuscular injection of Haloperidol decanoate is more effective in reducing patient pain than usual practice.

开始日期2023-09-01

申办/合作机构

Groupe Hospitalier Paul Guiraud

[+1]

NCT04327843 / Completed临床3期IIT

Reducing the Burden of Chronic Psychotic Disorders in Tanzania

The proposed, three phase project will refine and test a first-ever care approach in SSA that combines LAI with a behavioral program specifically intended to promote medication adherence in chronic psychotic disorders (CPDs). In addition to the novel focus, innovative elements include: 1.) a manualized curriculum that targets specific barriers and facilitators to medication adherence in Tanzanians with CPD, 2.) targeting known, high-risk individuals with CPD (those who miss ≥20% of prescribed antipsychotic medication, and 3.) using existing injection clinic health workers to deliver the adherence promotion program. Strengths include the highly generalizable methods and use of LAIs that are available in low-resource settings.

开始日期2019-11-05

申办/合作机构

Case Western Reserve University

[+1]

NCT01949662 / Active, not recruiting临床2期IIT

A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit

This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.

开始日期2014-01-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与癸酸氟哌啶醇相关的临床结果

登录后查看更多信息

100 项与癸酸氟哌啶醇相关的转化医学

登录后查看更多信息

100 项与癸酸氟哌啶醇相关的专利（医药）

登录后查看更多信息

365

项与癸酸氟哌啶醇相关的文献（医药）

2024-02-01·BMJ Case Reports

Atypical neuroleptic malignant syndrome in an incarcerated patient: a demographic who may be at increased risk

Article

作者: Kandukuri, Rajeev ; Zabel, Matthew

An incarcerated male patient with a psychiatric history of schizoaffective disorder presented to the emergency department with muscle rigidity and mutism after receiving a 150 mg haloperidol decanoate injection. At the peak of his illness, symptoms included muscular rigidity, mutism, excessive drooling, an altered level of consciousness, tachycardia, diaphoresis and tremors. Atypical neuroleptic malignant syndrome (NMS) was diagnosed after discrediting similar illnesses through clinical reasoning, laboratory and imaging studies. He was successfully treated during a 40-day hospitalisation with lorazepam, amantadine, methocarbamol and supportive care. This case represents an atypical presentation of NMS due to the patient’s lack of fever development. Nonetheless, he satisfied many other criteria, most notably rapid symptom onset after receiving a first-generation antipsychotic medication. The case also provides an opportunity to discuss the prevalence of psychiatric illness among the US incarcerated population and incarceration as a risk factor for developing NMS.

2023-10-20·Cureus

Haloperidol Decanoate-Induced Pancytopenia: A Case Report

作者: Gandhi, Raghu ; Veigne, Sandra ; Rizvi, Abid ; Jagtiani, Amit

Blood dyscrasias, including pancytopenia, can rarely occur as adverse effects of antipsychotic drug therapy. While neutropenia is more common, pancytopenia remains an infrequent but serious hematological complication. We present the case of an 85-year-old African-American female with a history of schizophrenia, stabilized on haloperidol decanoate, who developed pancytopenia during her outpatient care. Her blood counts progressively declined, leading to hospitalization. Hematology evaluation ruled out infectious or neoplastic causes, implicating haloperidol decanoate-induced pancytopenia. The pancytopenia improved gradually over three months after discontinuing haloperidol decanoate. Our case highlights the importance of monitoring and timely intervention in such cases. We discuss the rarity of pancytopenia with antipsychotics and the potential mechanisms and challenging management of this condition.

2023-10-01·Journal of child and adolescent psychopharmacology

Improved Treatment Outcome with Haloperidol Decanoate and Amantadine in an Adolescent with Schizoaffective Disorder.

Article

作者: Bez, Yasin ; Bernal, Julia A ; Zaydlin, Michelle ; Coffey, Barbara J

项与癸酸氟哌啶醇相关的新闻（医药）

2024-02-08

·蒲公英Ouryao

参比制剂目录（第77批）正式发布！

转自：国家药监局编辑：wangxinglai20042024年02月08日，国家药监局发布了第77批次仿制药一致性评价参比制剂目录，其中新增品种62个、变更及增加持证商品种30个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第七十七批）。涉及品种：利鲁唑口服混悬液、卡谷氨酸分散片、苹果酸奈诺沙星氯化钠注射液、甲磺酸贝舒地尔片、癸酸氟哌啶醇注射液、双氯芬酸钠外用溶液、双氯芬酸钾口服溶液用粉末、枸橼酸他莫昔芬口服溶液、甲苯磺酸尼拉帕利胶囊、达格列净二甲双胍片、注射用苄星青霉素、特考韦瑞胶囊、盐酸卡马替尼片、复方氨基酸（16）双肽（1）注射液、阿法骨化醇口服溶液、奥美沙坦酯阿折地平片、左氧氟沙星细粒剂、盐酸头孢卡品酯颗粒、乌帕替尼缓释片等；仿制药参比制剂目录（第77批）（扫描二维码下载附件）仿制药参比制剂目录（第77批）

一致性评价

2022-12-07

·GlobeNewswire-Health Care

Essential Pharma Announces the Acquisition of HALDOL®

Essential Pharma Announces the Acquisition of HALDOL® HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions The acquisition ensures access to this much-needed antipsychotic for patients and further strengthens Essential Pharma’s portfolio of specialist medicines across key therapeutic areas, particularly in CNS and GI domains Zug, Switzerland – 7 December, 2022 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of HALDOL® (haloperidol) and HALDOL® Decanoate (haloperidol decanoate) from Janssen Pharmaceutica NV. HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions such as schizoaffective disorder and moderate to severe manic episodes associated with bipolar I disorder. This medicine is included in the World Health Organization’s List of Essential Medicines. Under the terms of the acquisition, Essential Pharma has acquired the rights to HALDOL® on a global basis; the product is currently marketed in the US as well as in more than 60 countries across EMEA, Latin America and the Asia-Pacific regions. The acquisition is a further significant addition to Essential Pharma’s global portfolio of products in specialty central nervous system (CNS)/neurological medicine and underlines the group’s commitment to ensuring the sustained supply of essential medicines to patients. Steen Vangsgaard, CEO of Essential Pharma, commented: “Our aim is to ensure that every patient has access to the mature essential medicines they need. Haloperidol is an essential antipsychotic medicine marketed worldwide. This acquisition means that the patients who rely on this vital medicine can be assured of continued access; it also expands Essential Pharma’s global presence and further strengthens the concentration of our portfolio in CNS.” About Essential Pharma Essential Pharma is an international specialty pharmaceutical group dedicated to maintaining access to well-established, at-risk products essential to patients across multiple therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving patients access to medicines that otherwise might not be available. Essential Pharma operates globally in more than 60 countries, supplying a portfolio of over 150 essential medicines across multiple therapeutic areas. Essential Pharma's growth strategy is based on identifying and acquiring mature, at-risk products from larger pharmaceutical groups looking to streamline their product portfolios. It is a trusted partner to multiple pharma companies of all sizes, with a proven history of integrating assets and managing complex technology transfers seamlessly while ensuring continuous and sustainable supply to patients. Essential Pharma's growth strategy is backed by Gyrus Capital, an investment firm dedicated to transformational investments in sectors with long-term sustainable growth, including healthcare. For more information, please visit essentialpharmagroup.com CONTACTS Essential Pharma Steen Vangsgaard, CEO Tel: +44(0)1784 477 167 Email: info@essentialpharmaceuticals.com Consilium Strategic Communications Mary-Jane Elliott / Tracy Cheung / Matthew Cole Tel: +44 (0) 20 3709 5700 Email: Essentialpharma@consilium-comms.com

并购上市批准

100 项与癸酸氟哌啶醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01898	癸酸氟哌啶醇	N05AD01	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
精神分裂症	美国	Janssen Pharmaceuticals, Inc.	1986-01-14
Tourette 综合征	美国	Janssen Pharmaceuticals, Inc.	1986-01-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01152697 (CTgov)	N/A	分裂情感性障碍 \| 精神分裂症	30	Customized Adherence Enhancement+haloperidol decanoate+haloperidol	淵襯願蓋願壓製積鹹憲(遞鏇獵蓋艱簾鹹範築觸) = 齋廠憲膚鬱鏇鏇糧製獵積構糧窪獵鹹範繭觸鹹 (範襯簾構範顧網願餘壓, 齋積膚餘膚淵鬱積網鏇 ~ 夢顧選觸醖簾蓋構範鑰) 更多	-	2014-06-04
NCT01136772 (Pubmed)	临床4期	精神分裂症维持	311	Paliperidone palmitate	淵艱選淵製繭範範鹽觸(製範鏇鹹製窪膚觸壓廠) = 窪淵窪鏇願衊廠廠襯製鑰鏇艱鑰夢襯鏇網艱醖 (鬱夢製夢艱顧齋齋餘選, 29.75 ~ 39.37) 更多	-	2014-05-21
NCT01136772 (Pubmed)	临床4期	精神分裂症维持	311	Haloperidol decanoate	淵艱選淵製繭範範鹽觸(製範鏇鹹製窪膚觸壓廠) = 壓觸網觸齋鑰繭鹹選窪鑰鏇艱鑰夢襯鏇網艱醖 (鬱夢製夢艱顧齋齋餘選, 10.73 ~ 20.08) 更多	-	2014-05-21